Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 itepekimab study in inadequately controlled chronic rhinosinusitis with nasal polyps
MOH_2025-02-26_013892Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Itepekimab Q2W, Itepekimab Q4W with alternating placebo and Placebo Q2W (3 arms). Planned start Feb 2025; status: not yet recruiting.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on MOH_2025-02-26_013892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-26_013892.